Why Most Fund Strategies Break at Portfolio Construction
HealthVC’s latest essay warns that many venture fund strategies collapse during portfolio construction, not because of weak theses but due to flawed fund math. LPs scrutinize fund size, ownership stakes, reserve policies and exit assumptions to ensure the thesis can translate into cash returns. Emerging managers often over‑size funds, chase high‑profile logos without sufficient equity, or set unrealistic exit timelines, exposing a gap between narrative and economics. The piece previews the HealthVC Summit in Zurich, where LPs and GPs will dissect these mechanics across Europe, China and Saudi Arabia.
Clinical Value Is Not Commercial Value
Healthtech firms often mistake strong clinical data for commercial traction, overlooking the complex adoption machinery that governs hospital, payer, and pharma purchasing. The article argues that pilots and physician enthusiasm are insufficient unless they translate into budget authority, procurement pathways,...
Why LPs Say “Interesting” But Never Commit
HealthVC explains why limited partners (LPs) often label a fund "interesting" without committing capital. The term signals that a manager has passed an initial credibility test but lacks the internal urgency needed for allocation. Managers frequently misread engagement as momentum,...
What LPs Wish They Knew Before Backing a Fund Manager
The HealthVC newsletter reveals that many limited partners (LPs) evaluate fund managers on surface narratives and headline metrics, often missing deeper signals of repeatable skill. Seasoned LPs instead focus on a manager’s consistent decision‑making framework under uncertainty and dissect track...
The LP Allocation Filter No One Talks About
The article reveals that limited partners (LPs) use an invisible allocation filter that prioritizes how a new fund fits into an existing portfolio map rather than raw performance. Managers must contend with replacement risk, where each new commitment displaces an...
The Exit Optionality Trap: When Strategic Value Kills Venture Returns
The HealthVC newsletter warns that early strategic partnerships can trap health‑tech founders in a narrow exit path, sacrificing the optionality that drives higher valuations. While pharma interest feels like validation, it often anchors a company to a single buyer, reducing...
CMS Just Moved $13 Billion in Medicare Advantage Payments. Here's What Healthcare Investors Need to Know.
CMS announced a 2.48% Medicare Advantage rate increase for 2027, adding roughly $13 billion in federal payments. The agency also froze the risk‑adjustment model, reversing a proposed -3.32% recalibration that would have erased most growth. Simultaneously, CMS eliminated 11 Star Ratings...
The Reserve Strategy Illusion: Why Most Funds Misprice Follow-On Capital
HealthVC’s latest newsletter argues that the common claim of reserving 50% of a fund for follow‑on investments is largely a façade. While the reserve model looks disciplined on paper, real‑world outcomes—driven by power‑law returns and uneven company trajectories—turn the reserve...
Why Most Healthtech Funds Are Overestimating DPI Timelines
Healthtech venture funds are consistently overstating the speed at which they will return capital to investors. While many portfolios contain strong companies, models assume that clinical milestones and follow‑on rounds translate directly into exits, compressing the true liquidity horizon. In...
What Sovereign LPs Actually Care About
The HealthVC newsletter explains that sovereign limited partners (LPs) evaluate venture funds not by isolated performance but by how each fund fits into a broader, multi‑decade portfolio strategy. Their mandates focus on national objectives, geographic diversification, and strategic access, making...
HealthVC Summit 2026
HealthVC announced the inaugural HealthVC Summit 2026, a two‑day, invitation‑only event in Zurich on September 2‑3. The summit gathers European, Saudi and Chinese health‑tech investors and founders to discuss cross‑border capital flows in a closed, high‑trust setting. Unlike traditional conferences, there...
When Conviction Collapses Inside the VC Partnership
The piece dissects how conviction behind a Series A thesis can erode during internal investment‑committee debates, even when the memo is initially enthusiastic. It shows that individual partner belief must survive institutional dissent, and that reserve intensity, conditional language, and repeatability...